
Envisioning the reversal of oncogenesis
Abstract
Cancer, at different stages, is currently treated with conventional methods including chemotherapy, radiotherapy or surgery. These approaches often become ineffective for cancers that have spread aggressively in different parts of the body (metastasis). Hence, researchers have been actively investigating alternative methods to stop cancer-growth (oncogenesis) or even possibly reversing the cancer-growth (regression) without affecting the normal cells. Several approaches are used by scientists ranging from enhancing the immune system (immunotherapy) to genetic manipulations. Prophylactic vaccines are also attempted. An overview of such attempts is presented in this review. Several drugs developed at trial phases, or pre-clinical or exploratory phases are described. Many approaches show a promise of inhibiting oncogenesis, some also in its regression, thereby hinting at a possibility of finding a permanent solution to cancer in future.
Keywords
Full Text:
PDFReferences
Union of International Cancer Control.," WHO, Geneva, 2013.
Cancer: A neglecte health problem in developing countries.," International network for Cancer treatment and research, [Online]. Available: http://www.inctr.org/about-inctr/cancer-in-developing-countries
How many different types of cancer are there ?," Cancer Research UK, [Online]. Available: http://www.cancerresearchuk.org/cancer-help/about-cancer/cancer-questions/how-many-different-types-of-cancer-are-there.
Anand P, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B, Aggarwal BB: Cancer is a preventable disease that requires major lifestyle changes. Pharm. Res 2008, 25: 2097-2116.
http://dx.doi.org/10.1007/s11095-008-9661-9
PMid:18626751 PMCid:PMC2515569
Heredity and Cancer," American Cancer Society, 2013.
Trusheim MR, Berndt ER, Douglas FL: Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007, 6: 287-293.
http://dx.doi.org/10.1038/nrd2251
PMid:17380152
Vazquez A: Optimization of personalized therapies for anticancer treatment. BMC Systems Biology 2013, 7:31.
http://dx.doi.org/10.1186/1752-0509-7-31
PMid:23587292 PMCid:PMC3651412
Duarte FJ: Tunable Laser Applications. CRC, New York 2009, Chapters 5-8.
Dolmans DE, Fukumura D, Jain RK : Photodynamic therapy for cancer. Nat Rev cancer 2003, 3: 380-387.
http://dx.doi.org/10.1038/nrc1071
PMid:12724736
Damodar S, Terunuma H, Abraham S, Autologous Immune Enhancement Therapy (AIET) for a case of Acute Myeloid Leukemia (AML)- Our experience. Pasrm 2006, 2006-001.
Sivaraman G, Pandian A, Abraham S : Autologous Immune Enhancement therapy for Advanced Carcinoma of Pancreas-A Case Report. PASRM 2008.
Kleinman HK: Gene therapy for antiangiogenesis. J. Natl. Cancer Inst. 2001, 93: 965–967.
http://dx.doi.org/10.1093/jnci/93.13.965
PMid:11438554
Feldser DM, Kostova KK: Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 2010, 468: 572-575.
http://dx.doi.org/10.1038/nature09535
PMid:21107428 PMCid:PMC3003305
Alavanja MC: Biologic damage resulting from exposure to tobacco smoke and from radon: Implication for preventive interventions. Oncogene 2002, 21: 7365-7375.
http://dx.doi.org/10.1038/sj.onc.1205798
PMid:12379879
Hecht SS: Cigarette smoking and lung cancer: Chemical mechanisms and approaches to prevention. Lancet Oncol 2002, 3: 461-469.
http://dx.doi.org/10.1016/S1470-2045(02)00815-X
de Kok TM, van Maanen JM: Evaluation of fecal mutagenicity and colorectal cancer risk. Mutat Res 2000, 463: 53-101.
http://dx.doi.org/10.1016/S1383-5742(00)00003-X
Furumoto H, Irahara M: Human papilloma virus (HPV) and cervical cancer. J Med Invest, 2002, 49: 124-1233.
PMid:12323001
Davies JA: Inverse Correlation Between an Organ's Cancer Rate and Its Evolutionary Antiquity. Organogenesis 2004 1:2: 60-63.
http://dx.doi.org/10.4161/org.1.2.1338
PMid:20140231 PMCid:PMC2816350
Some stem cells tend to be more prone to cancer than the others. [Online]. Available: http://www.regenestem.com/some-stem-cells-are-more-susceptible-to-cancer-than-others/.
Lu C, Onn A, Vaporciyan AA: Cancer of the Lung. in Holland-Frei Cancer Medicine (8th ed.) ISBN 9781607950141, People's Medical Publishing House, 2010.
Singh S, Clarke I, Terasaki M, Bonn V, Hawkins C, Squire J, Dirks P: Identification of human brain tumor initiating cells. Nature 2004, 432: 396-401.
http://dx.doi.org/10.1038/nature03128
PMid:15549107
Sanai N, Tramontin AD, Quinones-Hinojosa A, Barbaro NM, Gupta N, Kunwar S, Lawton MT, McDermott MW, Parsa AT, Manueal-Garcia VJ, Berger MS, Alvarez-Buylla A: Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature 2004, 427: 740-744.
http://dx.doi.org/10.1038/nature02301
PMid:14973487
Sanai N, Alvarez-Buylla A, Berger M: Neural stem cells and the origin of gliomas. N Engl J Med 2005, 353: 811–822.
http://dx.doi.org/10.1056/NEJMra043666
PMid:16120861
"Heart cancer: Is there such a thing? - MayoClinic.com"," MayoClinic.com, 14 March 2009. [Online].
Ahuja P, Sdek P, Maclellan WR, Cardiac myocyte cell cycle control in development, disease and regeneration. Physiol Rev 2007, 87: 521-544.
http://dx.doi.org/10.1152/physrev.00032.2006
PMid:17429040 PMCid:PMC2708177
Todd R, Wong DT: Oncogenes. Anticancer Res 1999, 19: 4729–4746.
PMid:10697588
Sherr CJ: Principles of tumor suppression. Cell 2004, 116: 235–246.
http://dx.doi.org/10.1016/S0092-8674(03)01075-4
Klein CA: Cancer. The metastasis cascade. Science 2008, 321: 1785–1787.
http://dx.doi.org/10.1126/science.1164853
PMid:18818347
Chiang AC, Massagué J: Molecular basis of metastasis. N Eng J Med 2008, 359:. 2814–2823.
http://dx.doi.org/10.1056/NEJMra0805239
PMid:19109576
Pagano JS, Blaser M, Buendia MA, Damania B, Khalili K, Raab-Tarub N, Roizman B: Infectious agents and cancer: criteria for a causal relation. Semin. Cancer Biol. 2004, 14: 453–471.
http://dx.doi.org/10.1016/j.semcancer.2004.06.009
PMid:15489139
Herbst RS, Heymach JV, Lippman SM: Lung cancer. N Eng J Med 2008, 359: 1367–1380.
http://dx.doi.org/10.1056/NEJMra0802714
PMid:18815398
Rueth NM, Andrade RS: Is VATS lobectomy better: perioperatively, biologically and oncologically? Annals of Thoracic Surgery 2010, 89: S2107–S2111
http://dx.doi.org/10.1016/j.athoracsur.2010.03.020
PMid:20493991
Goldstein SD, Yang SC: Role of surgery in small cell lung cancer. Surg Oncol Clin N Amer 2011, 20: 769–777.
http://dx.doi.org/10.1016/j.soc.2011.08.001
PMid:21986271
Le Péchoux C: Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. Oncologist 2011, 16: 672–681.
http://dx.doi.org/10.1634/theoncologist.2010-0150
PMid:21378080 PMCid:PMC3228187
NSCLC Meta-Analyses Collaborative Group. Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials. J. Clin. Oncol 2008, 26.
PMid:18165637
Kelley AS, Meier DE: Palliative care—a shifting paradigm. N Eng J Med 2010, 363: 781-782.
http://dx.doi.org/10.1056/NEJMe1004139
PMid:20818881
Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH: Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level. J Amer. Med. Assoc 2006, 295: 65–73.
http://dx.doi.org/10.1001/jama.295.1.65
PMid:16391218
Cillo U, Vitale A, Bassanello M, Boccagni P, Borelese A, Zanus G, Burra P, Fagiuoli S: Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann. Surg. 2003, 239: 150-159.
http://dx.doi.org/10.1097/01.sla.0000109146.72827.76
PMid:14745321 PMCid:PMC1356206
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J, Oliviera A, Santoro A, Raoul J, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L: Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med 2008, 359: 378–390.
http://dx.doi.org/10.1056/NEJMoa0708857
PMid:18650514
Chen M, Li J, Zheng Y, Guo R, Liang H, Zhang Y, Lin X, Lau W: A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma. Annal Surgery 2006, 243: 321–328.
http://dx.doi.org/10.1097/01.sla.0000201480.65519.b8
PMid:16495695 PMCid:PMC1448947
Vente MA, Wondergem M, van der Tweel I: Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009, 19: 951–959.
http://dx.doi.org/10.1007/s00330-008-1211-7
PMid:18989675
Bernstein LR, van der Hoeven JJ, Boer RO: Hepatocellular carcinoma detection by gallium scan and subsequent treatment with gallium maltolate: rationale and case study. Anti-Cancer Agents Med Chem 2011, 11: 585–590.
http://dx.doi.org/10.2174/187152011796011046
PMid:21554205
Yamamoto J, Suichi O, Kazuaki S, Takushi O, Susumu Y, Hideki U, Tomoo K: Treatment strategy for small hepatocellular carcinoma: Comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatol 2001, 34: 707–713.
http://dx.doi.org/10.1053/jhep.2001.27950
PMid:11584366
Reeder JG, Vogel VG: Breast cancer prevention. Cancer treatment res 2008, 141: 149–164.
http://dx.doi.org/10.1007/978-0-387-73161-2_10
PMid:18274088
Yager JD: Estrogen carcinogenesis in breast cancer. N Engl J Med 2006, 354: 270–282.
http://dx.doi.org/10.1056/NEJMra050776
PMid:16421368
Gage M, Wattendorf D, Henry LR: Translational advances regarding hereditary breast cancer syndromes. J Surg Oncol 2012, 105: 444–451
http://dx.doi.org/10.1002/jso.21856
PMid:22441895
Pasche B: Cancer Genetics (Cancer Treatment and Research), Berlin: Springer, 2010: 19-20.
http://dx.doi.org/10.1007/978-1-4419-6033-7
Holmes MD, Chen WY, Chen LL, Hertzmark E, Speigelman D, Hankinson SE: Aspirin Intake and Survival After Breast Cancer. J Clin Oncol 2010, 28: 1467–1472.
http://dx.doi.org/10.1200/JCO.2009.22.7918
PMid:20159825 PMCid:PMC2849768
Petit T, Dufour P, Tannock I: A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer. Endocr. Relat. Cancer 2011, 18: R79–89.
http://dx.doi.org/10.1530/ERC-10-0162
PMid:21502311
Ahanzeb M: Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin. Breast Cancer 2008, 8: 324–333.
http://dx.doi.org/10.3816/CBC.2008.n.037
PMid:18757259
Belletti B, Vaidya JS, D'Andrea S: Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding. Clin. Cancer Res 2008, 14: 1325–1332.
http://dx.doi.org/10.1158/1078-0432.CCR-07-4453
PMid:18316551
Markowitz SD, Bertagnolli MM: Molecular Origins of Cancer: Molecular Basis of Colorectal Cancer. N. Engl. J. Med 2009, 361: 2449–2460.
http://dx.doi.org/10.1056/NEJMra0804588
PMid:20018966 PMCid:PMC2843693
Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med 2004, 10: 789–799.
http://dx.doi.org/10.1038/nm1087
PMid:15286780
Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, Fowler G, Kovar CL, Lewis LR: Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487: 330–337.
http://dx.doi.org/10.1038/nature11252
PMid:22810696 PMCid:PMC3401966
Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N: Colorectal cancer. Lancet 2010, 375: 1030–1047.
http://dx.doi.org/10.1016/S0140-6736(10)60353-4
Chemotherapy of metastatic colorectal cancer. Prescrire Int 2010, 19: 219–224.
PMid:21180382
Wasserberg N, Kaufman HS: Palliation of colorectal cancer. Surg Oncol 2007, 16: 299–310.
http://dx.doi.org/10.1016/j.suronc.2007.08.008
PMid:17913495
Dennis LK, Coughlin JA, McKinnon BC, Wells TS, Gaydos CA, Hamsikova E, Gray GC: Sexually transmitted infections and prostate cancer among men in the U.S. military Cancer epidemiology, biomarkers & prevention. Amer Assoc cancer Res 2009, 18: 2665-2671.
Leav I, Plescia J, Goel HL, Li J, Jiang Z, Cohen RJ, Languino LR, Altieri DC. Cytoprotective Mitochondrial Chaperone TRAP-1 As a Novel Molecular Target in Localized and Metastatic Prostate Cancer. Am. J. Pathol. 2010, 176: 393–401.
http://dx.doi.org/10.2353/ajpath.2010.090521
PMid:19948822 PMCid:PMC2797899
Zha J, Huang YF: TGF-beta/Smad in prostate cancer: an update. Zhonghua Nan Ke Xue 2009, 15: 840–843.
PMid:19947572
Senapati S, Rachagani S, Chaudhary K, Johansson SL, Singh RK, Batra SK: Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK–RhoA signaling pathway. Oncogene 2010, 29: 1293–1302.
http://dx.doi.org/10.1038/onc.2009.420
PMid:19946339 PMCid:PMC2896817
Hong H, Zhang Y, Sun J, Cai W: Positron emission tomography imaging of prostate cancer. Amino Acids 2009, 39: 11–27.
http://dx.doi.org/10.1007/s00726-009-0394-9
PMid:19946787 PMCid:PMC2883014
Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P: Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy 2011, 31: 813–828.
http://dx.doi.org/10.1592/phco.31.8.813
PMid:21923608
Nativ O, Witjes JA, Hendricksen K, Cohen M, Kedar D, Sidi A, Colombo R, Leibovitch I: Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. Jour Urol 2009, 182: 1313–1317.
http://dx.doi.org/10.1016/j.juro.2009.06.017
PMid:19683278
Halachmi S, Moskovitz B, Maffezzini M et al: Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol 2009, 29: 259–264.
http://dx.doi.org/10.1016/j.urolonc.2009.02.012
PMid:19395285
Majid S , Saini S, Dahiya R: Wnt signaling pathways in urological cancers: past decades and still growing.Review. Mol Cancer 2012, 11:7 doi: 10.1186/1476-4598-11-7.
http://dx.doi.org/10.1186/1476-4598-11-7
Sanchez-Carvayo M, Capodieci P, Cordon-Cardo C . Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome. Am J Pathol 2003, 162: 609-617.
http://dx.doi.org/10.1016/S0002-9440(10)63854-0
Keyes WM, Pecoraro M, Aranda V, Vernersson-Lindahl E, Li W, Vogel H, Guo X, Garcia EL, Michurina TV, Enikopolov G, Muthuswamy SK, Mills AA: Np63 alpha Is an Oncogene that Targets Chromatin Remodeler Lsh to Drive Skin Stem Cell Proliferation and Tumorgenesis. Cell Stem Cell 2011, 8: 164-176.
http://dx.doi.org/10.1016/j.stem.2010.12.009
PMid:21295273
"What causes melanoma skin cancer?" http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-what-causes," [Online].
Lind MH, Rozell B, and Walin RPA et al: Tumor necrosis factor receptor 1 mediated signaling is required for skin cancer development induced by NF-kB inhibition. PNAS 2004, 101: 4972-4977.
http://dx.doi.org/10.1073/pnas.0307106101
PMid:15044707 PMCid:PMC387358
Panelos J, Massi D: Emerging role of Notch signaling in epidermal differentiation and skin cancer. Cancer Biol Ther 2009, 8: 1986-1993.
http://dx.doi.org/10.4161/cbt.8.21.9921
PMid:19783903
Doherty GM, Gerard M, Mulholland MW: Greenfield's Surgery: Scientific Principles And Practice. Baltimore: Williams & Wilkins ISBN 0-7817-5626-X., 2005.
Furge KA, Tan MH, Dykema K et al: Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenic approach based on gene expression profiling. Review. Oncogene 2007, 26: 1346-1350
http://dx.doi.org/10.1038/sj.onc.1210256
PMid:17322920
Jonasch E, Messner C: CancerCare Connect - Treatment Update: Kidney Cancer," Cancer Care, Inc, 2012.
Advanced kidney cancer : Cancer Research UK : CancerHelp UK.
Niederacher D, An HX, Cho YJ, Hantschmann P, Bender HG, Beckmann MW: Mutations and amplification of oncogenes in endometrial cancer. Oncol 1999, 5: 6596-6565.
Kim TH, Lee DK, Cho SN, Orvis GD, Behringer RR, Lydon JP, Ku BJ, McCampbell AA, Broadddus RR, Jeong JW. Critical Tumor Suppressor Function Mediated by Epithelial Mig-6 in Endometrial Cancer. Cancer Res 2013, 73: 5090-5099.
http://dx.doi.org/10.1158/0008-5472.CAN-13-0241
PMid:23811943
Yamazawa K, Shimada H, Hirai M, Hirashiki K, Ochiai T, Ishikura H, Shozu M, Isaka K: Serum p53 antibody as a diagnostic marker of high-risk endometrial cancer. American journal of obstetrics and gynecology 2007, 197:505. e501-505. e507.
http://dx.doi.org/10.1016/j.ajog.2007.04.033
" Uterine Sarcomas - Hormonal Therapy," American Cancer Society, 2007.
Freeman JW, DeArmond D, Lake M, Huang W, Venkatasubbarao K, Zhao S: Alterations of cell signaling pathways in pancreatic cancer. Front Biosci 2004, 9: 1889-1998
http://dx.doi.org/10.2741/1388
PMid:14977595
Eser S, Reiff N, Messer M et al: Selective Requirement of PI3K/PDK1 Signaling for Kras Oncogene-Driven Pancreatic Cell Plasticity and Cancer. Cancer Cell 2013, 23: 406-420.
http://dx.doi.org/10.1016/j.ccr.2013.01.023
PMid:23453624
Corbo V, Tortora G, Scarpa A: Molecular pathology of pancreatic cancer: from bench-to-bedside translation. Curr Drug Targets 2012, 13: 744-752.
http://dx.doi.org/10.2174/138945012800564103
PMid:22458520 PMCid:PMC3419918
Neoptolemos JP, Stocken DD, Friess H et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350: 1200–1210.
http://dx.doi.org/10.1056/NEJMoa032295
PMid:15028824
Moore MJ, Goldstein D, Hamm J et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Clin Oncol 2007, 25: 1960-1966.
http://dx.doi.org/10.1200/JCO.2006.07.9525
PMid:17452677
Pompetti F, Rizzo P, Simon RM, Freidlin B, Mew DJ, Pass HI, Picci P, Levine AS, Carbone M: Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem 1996, 63: 37-50.
http://dx.doi.org/10.1002/(SICI)1097-4644(199610)63:1<37::AID-JCB3>3.0.CO;2-0
Kingsley LA, Fournier PJ, Chirgwin JM, Guise TA: Molecular Biology of Bone Metastasis. Mol Cancer Ther 2007, 6: 2609-2617.
http://dx.doi.org/10.1158/1535-7163.MCT-07-0234
PMid:17938257
Harris AL: Hypoxia - a key regulatory factor in tumour growth. Review. Nat Rev Cancer 2002, 2: 38-47.
http://dx.doi.org/10.1038/nrc704
PMid:11902584
FDA ANDA Generic Drug Approvals, Food and Drug Administration.
Chandana SR, Movva S, Arora M, Singh T: Primary Brain Tumors in Adults. Am Fam Physician 2008, 77: 1423-1430.
PMid:18533376
Steck PA, Saya H: Pathways of oncogenesis in primary brain tumors. Curr Opin Oncol 1991, 3: 4764-84.
http://dx.doi.org/10.1097/00001622-199106000-00006
"MD Anderson team identifies new oncogene for brain tumors". http://www.mdanderson.org/newsroom/news-releases/2007/m-d-anderson-team-identifies-new-oncogene-for-brain-tumors.html," 2007. [Online].
Shibuya M, Yamazaki H, Ohba Y, Fukui Y, Jeyama Y, Tamaoki N: Activation of Proto-Oncogenes in Human Brain Tumors. Biological Aspects of Brain Tumor, Springer 1991, 28-37.
http://dx.doi.org/10.1007/978-4-431-68150-2_3
Stockhausen MT, Kristoffersen K, Poulsen HS: Notch signaling and brain tumors. Adv Exp Med Bio 2012, 727: 289-304.
http://dx.doi.org/10.1007/978-1-4614-0899-4_22
PMid:22399356
Whole Brain Radiation increases risk of learning and memory problems in cancer patients with brain metastases, MD Anderson Cancer Center, 2012.
How Our Patients Perform : Glioblastoma Multiforme, UCLA Neuro-Oncology Program, 2012.
"Normal Pressure Hydrocephalus Causes, Symptoms, Treatment – Next Steps on eMedicineHealth," 2012. [Online]. Available: Emedicinehealth.com.
Ridanpää M, Lothe RA, Onfelt A, Børresen AL, Husgafvel-Pursiainen K: K-ras oncogene codon 12 point mutations in testicular cancer. Envl Health Pers 1993, 101 Suppl 3: 185-187.
Shyu RY, Wu CC, Wang CH, Tsai TC, Wang LK, Chen MK, Jiang SY, Tsai FM: H-rev107 regulates prostaglandin D2 synthase-mediated suppression of cellular invasion in testicular cancer cells. J Biomed Sci 2013, 20: 30.
http://dx.doi.org/10.1186/1423-0127-20-30
PMid:23687991 PMCid:PMC3669107
Vladusic T, Hrascan R, Pecina-Slau N, Vrhovac I, Gamulin M, Franekic J, Kruslin B: Loss of heterozygosity of CDKN2A (p16INK4a) and RB1 tumor suppressor genes in testicular germ cell tumors. Radiol Oncol 2010, 44: 168-173.
http://dx.doi.org/10.2478/v10019-010-0035-7
PMid:22933911 PMCid:PMC3423692
Boyer A, Paquet M, Laguë MN, Hermo L, Boerboom D: Dysregulation of WNT/CTNNB1 and PI3K/AKT signaling in testicular stromal cells causes granulosa cell tumor of the testis. Carcinogenesis 2009, 30: 869-878, 2009.
http://dx.doi.org/10.1093/carcin/bgp051
PMid:19237610 PMCid:PMC2675650
Gadducci A, Barsotti C, Cosio S, Domenici L, Riccardo Genazzani A: Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gyn endoc 2011, 27: 597-604.
Yoon SK, Lim NK, Ha SA et al: The Human Cervical Cancer Oncogene Protein Is a New Biomarker for Human Hepatocellular Carcinoma. Cancer Res 2004, 64: 5434-5441.
http://dx.doi.org/10.1158/0008-5472.CAN-03-3665
PMid:15289352
Faridi R, Zahra A, Khan K, Idrees M: Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer. Review. Virol J 2011, 8: 269 doi: 10.1186/1743-422X-8-269.
http://dx.doi.org/10.1186/1743-422X-8-269
Erstad S: Cone biopsy (conization) for abnormal cervical cell changes," WebMD, 2007.
Plante M, Renaud MC, Hoskins IA, Roy M: Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature. Gynecol. Oncol. 2005, 98: 3–10.
http://dx.doi.org/10.1016/j.ygyno.2005.04.014
PMid:15936061
Veena MS, Lee G, Keppler D, Mendonca MS, Redpath J, Stanbridge EJ, Wilczynski SP, Srivatsan ES: Inactivation of the cystatin E/M tumor suppressor gene in cervical cancer. Genes Chromosomes Cancer. Genes Chromosomes Cancer 2008, 47: 740-754.
http://dx.doi.org/10.1002/gcc.20576
PMid:18506750 PMCid:PMC2974630
Cohen Y, Singer G, Lavie O, Dong SM, Beller U, Sidransky D: The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin Cancer Res 2003, 9: 2981-2984.
PMid:12912945
Maity G, Fahreen S, Banerji A, Roy Choudhury P, Sen T, Dutta A, Chatterjee A: Fibronectin-integrin mediated signaling in human cervical cancer cells (SiHa). Mol Cell Biochem 2010, 336: 65-74.
http://dx.doi.org/10.1007/s11010-009-0256-5
PMid:19816757
Shin WS, Kwon J, Lee HW et al: Oncogenic role of protein tyrosine kinase 7 in esophageal squamous cell carcinoma. Cancer Sci 2013, 104: 1120–1126.
http://dx.doi.org/10.1111/cas.12194
PMid:23663482
Rousseau MC, Hsu RY, Spicer JD, McDonald B, Chan CH, Perera RM, Giannias B, Chow SC, Rousseau S, Law S, Ferri LE: Lipopolysaccharide-induced toll-like receptor 4 signaling enhances the migratory ability of human esophageal cancer cells in a selectin-dependent manner. Surgery 2013, 154: 69-77.
http://dx.doi.org/10.1016/j.surg.2013.03.006
PMid:23809486
Sui G, Bonde P, Dhara S, Broor A, Wang J, Marti G: Epidermal growth factor receptor and hedgehog signaling pathways are active in esophageal cancer cells from rat reflux model. J Surg Res 2006, 134: 1-9.
http://dx.doi.org/10.1016/j.jss.2005.12.029
PMid:16488438
Li B, Li YY, Tsao SW et al: Targeting NF-κB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer. Mol Cancer Ther 2009, 8: 2635-2644.
http://dx.doi.org/10.1158/1535-7163.MCT-09-0162
PMid:19723887
Pouw RE, Wirths K, Bergman JJ et al: Efficacy of Radiofrequency Ablation Combined with Endoscopic Resection for Barrett's Esophagus with Early Neoplasia. Clinl Gastroent Hepatol 2010, 8: 23-30.
http://dx.doi.org/10.1016/j.cgh.2009.07.003
PMid:19602454
Enger E, Ross F, Bailey D: Concepts in Biology, 14 ed., McGraw-Hill, 2011.
Kleinman HK, Liau G: Gene therapy for antiangiogenesis. J. Natl. Cancer Inst 2001, 93: 965–967.
http://dx.doi.org/10.1093/jnci/93.13.965
PMid:11438554
Tree AC, Khoo VS, Eeles RA; Ahmed M, Dearnaley DP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ, as Van NJ: Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013, 14: e28-37
http://dx.doi.org/10.1016/S1470-2045(12)70510-7
Masihi KN: Fighting infection using immunomodulatory agents. Expert Opin Biol Ther 2001, 1: 641-653.
http://dx.doi.org/10.1517/14712598.1.4.641
PMid:11727500
Tongyoo A: Targeted therapy: novel agents against cancer. J Med Assoc Thai 2010, 93 Suppl 7, S311-23.
PMid:21294432
Larsen JE, Cascone T, Gerber DE, Heymach JV, Minna JD: Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J 2011, 17: 512-527.
http://dx.doi.org/10.1097/PPO.0b013e31823e701a
PMid:22157296 PMCid:PMC3381956
Kassouf W, Brown GA, Black PC, Fisher MB, Inamoto T, Luongo T: Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer? J Urol 2008, 180: 1146-53.
http://dx.doi.org/10.1016/j.juro.2008.05.001
PMid:18639280
Brahmer JR, Tykodi SS, Chow LQ et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Eng J Med 2012, 366: 2455-2465.
http://dx.doi.org/10.1056/NEJMoa1200694
PMid:22658128 PMCid:PMC3563263
Jacobs MA, Wotkowicz C, Baumgart ED, Neto BS, Rieger-Christ KM, Bernier T: Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib. J Urol 2007, 178: 1510-1514.
http://dx.doi.org/10.1016/j.juro.2007.05.113
PMid:17707060
Yang JL, Qu XJ, Hayes VM, Brenner PC, Russell PJ, Goldstein D: Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha. BJU Int 2007, 99: 1539-1545.
http://dx.doi.org/10.1111/j.1464-410X.2007.06778.x
PMid:17346275
Hodi FS, Mihm MC, Soiffer RJ et al: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. PNAS 2003, 100: 4712-4717
http://dx.doi.org/10.1073/pnas.0830997100
PMid:12682289 PMCid:PMC153621
Erivedge (vismodegib) package insert. [Performance]. Genentech, South San Francisco CA, 2012.
Yervoy (ipilimumab) package insert. [Performance]. Bristol-Myers Squibb, Princeton NJ, 2011.
De Smaele E, Ferretti E, Gulino A: Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. Curr Opin Investig Drugs 2010, 11:707-718.
PMid:20496266
(ClinicalTrials.gov Identifier:NCT01271972).
"http://investor.regeneron.com/releasedetail.cfm ReleaseID=737801," [Online].
Bargou R, Leo E, Zugmaier G et al: Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 15: 974-977.
http://dx.doi.org/10.1126/science.1158545
PMid:18703743
Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP: A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res 2007, 13: 1810–1815.
http://dx.doi.org/10.1158/1078-0432.CCR-06-2318
PMid:17363537
Thakur A, Vaishampayan U, Lawrence G: Immunotherapy and Immune Evasion in Prostate Cancer. Cancers 2013, 5: 569-590.
http://dx.doi.org/10.3390/cancers5020569
PMCid:PMC3730318
Gabrilovich DI: Myeloid-derived suppressor cells and tumor microenvironment. J. Immunother 2009, 32: 987–988.
Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM: Gemcitabine selectively eliminates splenic Gr-1(+)/CD11b(+) myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res 2005, 11: 6713–6721.
http://dx.doi.org/10.1158/1078-0432.CCR-05-0883
PMid:16166452
Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD: Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009, 9: 900-909.
http://dx.doi.org/10.1016/j.intimp.2009.03.015
PMid:19336265
Clinical trials of Oncoerythyreon using tecemotide http://www.oncothyreon.com/clinical/Tecemotide.html
Wu YL, Park K, Soo RA, Sun Y, Tyroller K, Wages D, Ely G, Yang JC, Mok T: INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer 2011, 11: doi: 10.1186/1471-2407-11-430.
http://dx.doi.org/10.1186/1471-2407-11-430
Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM: Translating Tumor Antigens into Cancer Vaccines. Clin Vacc Immunol 2011, 18: 23-24.
http://dx.doi.org/10.1128/CVI.00286-10
PMid:21048000 PMCid:PMC3019775
de Cerio AL, Zabalegui N, Rodgriguez-Calvillo M, Inoges S, Bendandi M: Anti-idiotype antibodies in cancer treatment. Oncogene 2007, 26: 3594-3602.
http://dx.doi.org/10.1038/sj.onc.1210371
PMid:17530013
Palucka K, Banchereau J: Dendritic-Cell-Based Therapeutic Cancer Vaccines. Immunity 2013, 39: 38-48.
http://dx.doi.org/10.1016/j.immuni.2013.07.004
PMid:23890062
Stevenson FK, Ottensmeier CH, Johnson PEA: DNA vaccines to attack cancer. PNAS 2004, 101 Suppl 2: 14646-14652.
http://dx.doi.org/10.1073/pnas.0404896101
PMid:15292504 PMCid:PMC521995
Teshima T, Mach N, Hill GR et al: Tumor Cell Vaccine Elicits Potent Antitumor Immunity after Allogeneic T-Cell-depleted Bone Marrow Transplantation. Cancer res 2001, 61: 162–171.
PMid:11196155
Nemunaitis J: Oncolytic viruses. Investigational new drugs 1999, 17: 375–386.
http://dx.doi.org/10.1023/A:1006334404767
PMid:10759404
Melcher A, Parato K, Rooney CM, Bell JC: Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide. Mol Ther 2011, 19: 1008–1016.
http://dx.doi.org/10.1038/mt.2011.65
PMid:21505424 PMCid:PMC3129809
Meerani S, Yao Y: Oncolytic Viruses in Cancer Therapy. Eur J Sci Res 2010, 40: 156 -171.
Bourke MG, Salwa S, Harrington KJ, Kucharczyk MJ, Forde PF, de Kruijf M, Soden D, Tangney M, Collins JK, O' Sullivan GC: The emerging role of viruses in the treatment of solid tumours. Cancer Treat Rev 2011, 37: 618-632.
http://dx.doi.org/10.1016/j.ctrv.2010.12.003
PMid:21232872
MacLean AR, ul-Fareed M, Robertson L, Harland J, Brown SM: Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol 1991, 72: 631-639.
http://dx.doi.org/10.1099/0022-1317-72-3-631
PMid:1848598
Braidwood L, Dunn PD et al: Antitumor activity of a selectively replication competent herpes simplex virus (HSV) with enzyme prodrug therapy. Anticancer Res 2009, 29: 2159-2166.
PMid:19528476
MacKie RM, Stewart B, Brown SM: Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. The Lancet 2011, 357: 525-526.
http://dx.doi.org/10.1016/S0140-6736(00)04048-4
Mace AT, Ganly I et al: Potential for efficacy of the oncolytic herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head & Neck 2008, 30: 1045-1051.
http://dx.doi.org/10.1002/hed.20840
PMid:18615711
Garber K: China Approves World's First Oncolytic Virus Therapy for Cancer Treatment. J Nat Cancer Inst 2006, 98: 298–300.
http://dx.doi.org/10.1093/jnci/djj111
PMid:16507823
"Gene Therapy," MD Anderson, [Online]. Available: http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-topics/cancer-treatment/chemotherapy/gene-therapy/index.html.
Kershaw MH, Westwood JA, Darcy PK: Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013, 13: 525-541.
http://dx.doi.org/10.1038/nrc3565
PMid:23880905
Heslop HE: Genetic engineering of T-cell receptors: TCR takes to titin. Blood 2013, 122: 853-854.
http://dx.doi.org/10.1182/blood-2013-06-509604
PMid:23929832
Huang TT, Hlavaty J, Ostertag D, Espinoza FL et al: Toca 511 gene transfer and 5-fluorocytosine in combination of temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide sensitive glioblastoma model. Cancer Gene Ther 2013.
http://dx.doi.org/10.1038/cgt.2013.51
Starlard-Davenport A, Kutanzi K, Tryndyak V, Word B, Lyn-Cook B: Restoration of the methylation status of hypermethylated gene promoters by microRNA-29b in human breast cancer: A novel epigenetic therapeutic approach. J. Carcinogenesis 2013, 12:15.
http://dx.doi.org/10.4103/1477-3163.115720
PMid:23961262 PMCid:PMC3746452
"What Is Cancer Screening?," National Cancer Institute, [Online]. Available: http://www.cancer.gov/cancertopics/screening.
Wilson JM, Jungner G: Principles and practice of screening for disease. World Health Organization. Public Health Papers, #34, 1968.
Morgan JE, Carr IM, Sheridan E et al: Genetic diagnosis of familial breast cancer using clonal sequencing. Hum mutat 2010, 31: 484-491.
http://dx.doi.org/10.1002/humu.21216
PMid:20127978
Meldrum C, Doyle MA, Tothill RW: Next-Generation Sequencing for Cancer Diagnostics: a Practical Perspective. Review. Clin Biochem Rev 2011, 32: 177-195.
PMid:22147957 PMCid:PMC3219767
Narayan A, Carriero NJ, Gettinger SN, et al: Ultrasensitive Measurement of Hotspot Mutations in Tumor DNA in Blood Using Error-Suppressed Multiplexed Deep Sequencing. Cancer Res 2012, 72: 3492-3498.
http://dx.doi.org/10.1158/0008-5472.CAN-11-4037
PMid:22581825 PMCid:PMC3426449
Li M, Diehl F, Dressman D, Vogelstein B, Kinzler KW: BEAMing up for detection and quantification of rare sequence variants. Nat methods 2006, 3: 95-97.
http://dx.doi.org/10.1038/nmeth850
PMid:16432518
Screening for Cervical Cancer, U.S. Preventive Services Task Force, March 2012. [Online]. Available: http://www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/cervcancerfact.pdf.
Tonus C, Sellinger M: Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: A meta-analysis. World J Gastroent 2012, 18: 4004-4011.
http://dx.doi.org/10.3748/wjg.v18.i30.4004
PMid:22912551 PMCid:PMC3419997
Ahrens M J, Bertin PA, Vonesh EF, Meade TJ, Catalona WJ, Georganopoulou D: PSA enzymatic activity: A new biomarker for assessing prostate cancer aggressiveness. Prostate 2013, doi: 10.1002/pros.22714.
http://dx.doi.org/10.1002/pros.22714
Jacklitsch MT, Jacobson FL, Austin JHM, Field JK et al: The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac cardiovas Surg 2012, 144: 33-38
"Jack Andraka the teen prodigy of pancreatic cancer," Smithsonian Magazine, 2012. [Online]. Available: http://www.smithsonianmag.com/science-nature/Jack-Andraka-the-Teen-Prodigy-of-Pancreatic-Cancer-179996151.html.
"Circulating Mesothelin Serves as a Marker of Pancreatic Cancer," 22 October 2009. [Online]. Available: http://phys.org/news175447210.html.
Johnston FM, Tan MC B, Tan Jr BR, Porembka MR, et al: Circulating Mesothelin Protein and Cellular anti-Mesothelin Immunity in Patients with Pancreatic Cancer. Clin Cancer Res 2009, 15: 6511-6518.
http://dx.doi.org/10.1158/1078-0432.CCR-09-0565
PMid:19843662 PMCid:PMC2782601
Polanski M, Leigh Anderson N: A list of candidate cancer biomarkers for targeted proteomics. Review. Biomarker Insights 2006, 2:1-48.
Hanausek M, Walaszek Z, Slaga TJ: Detoxifying cancer causing agents to prevent cancer. Integr Cancer Ther 2003, 2: 139-144.
http://dx.doi.org/10.1177/1534735403002002005
PMid:15035900
Zhao B, Wang Y, Wu B: Placenta-derived gp96 as a multivalent prophylactic cancer vaccine. Scientific reports 2013, 3: 1-7.
Yaddanapudi K, Robert A, Putty MK, Willer S, Sharma RK, Yan J, Bodduluri H, Eaton JW: Vaccination with Embryonic Stem Cells Protects against Lung Cancer: Is a Broad-Spectrum Prophylactic Vaccine against Caner possible? PLoS One 2012, 7: 1-12.
http://dx.doi.org/10.1371/journal.pone.0042289
PMid:22860107 PMCid:PMC3409174
Waknine Y: International Approvals: Singulair and Gardasil/Silgard," Medscape Today, 2008.
Lowy DR, Schiller JT: Prophylactic human papillomavirus vaccines. J. Clin. Invest 2006, 116: 1167–1173.
http://dx.doi.org/10.1172/JCI28607
PMid:16670757 PMCid:PMC1451224
Gardasil Vaccine Safety. Vaccine Safety & Availability," U.S. Food and Drug Administration (FDA), 2009.
DOI: http://dx.doi.org/10.14259%2Fcs.v1i2.64
Refbacks
- There are currently no refbacks.